Curio Wealth’s Cadrenal Therapeutics CVKD Stock Holding History

Curio Wealth’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$5	–	325
2026 Q1	$5	Hold	1	–	–	﹤0.01%	1245
2025 Q4	$7	Buy	+1	New	+$11	﹤0.01%	460

Other funds holding CVKD

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

GBT

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Curio Wealth's CVKD Position: Q2 2026 in Review

Curio Wealth sold out of Cadrenal Therapeutics (CVKD) in Q2 2026, closing a stake of 1 share — an estimated $5 sold.

Curio Wealth first reported a position in CVKD in Q4 2025 and held it in 2 quarters. The position peaked at $7 in Q4 2025. 19 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

Curio Wealth reported no remaining Cadrenal Therapeutics position as of Q2 2026 after selling out during the quarter.
Curio Wealth sold 1 Cadrenal Therapeutics share in Q2 2026, an estimated $5.
Curio Wealth first reported a position in Cadrenal Therapeutics in Q4 2025 and held it in 2 quarters.
Curio Wealth's Cadrenal Therapeutics position peaked at $7 in Q4 2025.
19 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Curio Wealth's 13F filing for Q2 2026, filed 7 Aug 2026.